EU boosts Pfizer vaccine supply with German site approvals

Syringes are seen at the Impfzentrum Basel Stadt vaccination center in Basel
Syringes containing Pfizer-BioNTech COVID-19 vaccine are seen at the Impfzentrum Basel Stadt vaccination center at the Congress Center of the Messe Basel fairground, as the spread of the coronavirus disease (COVID-19) continues, in Basel, Switzerland March 18, 2021. REUTERS/Arnd Wiegmann/File Photo

Sept 9 (Reuters) - The European Union's drugs regulator on Thursday approved an increase in manufacturing capacity for the COVID-19 vaccine from Pfizer/BioNTech (PFE.N), (22UAy.DE), which would help produce up to 50 million additional doses this year.

Both approved sites are located in Germany. One of them is operated by Sanofi-Aventis Deutschland Gmb (SASY.PA) and the other is operated by Siegfried Hameln GmbH (SFZN.S), the European Medicines Agency said.

Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur

Our Standards: The Thomson Reuters Trust Principles.

Read Next